Trials / Completed
CompletedNCT02790489
Tolerance Study of the Dietary Supplement Valedia
Valedia Dietary Supplement Tolerance Study Based on Blood, Urinary and Hemodynamic Biological Parameters
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Valbiotis · Industry
- Sex
- Male
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objectives of this clinical study are to determine the tolerance of dietary supplement Valedia (blend of plant extracts) through the evaluation of several parameters : * Various blood biological parameters for tolerance (preprandial): blood glucose, insulin, fructosamine, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, oxidized LDL, us-CRP, creatinine, ASAT, ALAT, gGT, phosphatase alcaline, bilirubine, urea. * Urinary parameters: urea, creatinine. * Hemodynamic parameters: heart rate and blood pressure. * Cardiac function: ECG. * Weight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Valedia |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2016-06-06
- Last updated
- 2016-08-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02790489. Inclusion in this directory is not an endorsement.